Source: https://peakpeptides.com/peptides/cjc-1295-ipamorelin/ Peptide library · Growth hormone # CJC-1295 + Ipamorelin Two different peptides combined: a growth-hormone-releasing hormone analogue and a ghrelin-receptor agonist. The premixed combination lacks direct human trials, and the two components have separate FDA compounding histories. Last reviewed September 22, 2026 At a glance - **Also called:** CJC/Ipa; GHRH plus GHRP blend - **What it is:** A two-peptide GH-axis combination - **Evidence:** No direct human trial of the combination - **FDA status:** Neither component is FDA-approved - **In sport:** Both components are prohibited at all times - **At Promise Peptides:** Listed; currently waitlist-only The short version CJC-1295 + Ipamorelin combines two peptides that approach the growth-hormone axis from different receptors. CJC-1295 is a modified GHRH analogue; ipamorelin is a five-amino-acid agonist of the ghrelin receptor. General neuroendocrine biology suggests the pathways can interact, but no peer-reviewed human pharmacology study has tested the premixed combination itself. Neither peptide is FDA-approved. CJC-1295 and ipamorelin appear differently in FDA’s compounding tables, so one status cannot be assigned to both. A licensed provider’s clinical decision does not change those FDA facts. ## What it is CJC-1295 is an engineered analogue of the first 29 amino acids of human growth-hormone-releasing factor. The form called CJC-1295 with DAC includes a chemical group designed to bind albumin; a no-DAC form is also called modified GRF(1-29). Ipamorelin is a separate synthetic pentapeptide that activates the ghrelin receptor, GHS-R1a. Neither is naturally present in the administered form. The name describes a mixture rather than one molecule, so it has no single formula, sequence or CAS number. CJC-1295 with DAC has a reported molecular weight of 3,647.3 daltons; ipamorelin has a molecular weight of 711.86 daltons and is also called NNC 26-0161. Claims must identify which CJC form and which component a paper actually studied. ## Where the research stands The cited research does not include a human trial of the fixed combination. It includes general GH-axis reviews, class-level GHRH and ghrelin-receptor research, animal work on ipamorelin and analytical studies that detect these peptides. Those sources explain a hypothesis, not a demonstrated combined outcome. How far the evidence has climbed 1. Cell studies · None · No fixed-combination cell study cited 2. Animal studies · None · Components and related agonists only 3. Small human pilots · None · No human pilot of the mixture 4. Controlled human trials · None · No direct combination trial 5. FDA approval · No · Neither component is approved Here is what selected research looked at. Each card names the actual model and does not present it as evidence for the combined prescription. - **Human growth-hormone aging biology** (Scientific statement · 2023): An Endocrine Society statement reviewed how natural growth-hormone secretion changes with age. It did not test CJC-1295, ipamorelin or their combination as a treatment.[1] - **GHRH and ghrelin pathways** (Review · 2021): A neuroendocrine review described how ghrelin signaling can facilitate GHRH release and affect somatostatin. That circuit is the rationale for combining pathways, not proof about this formulation.[2] - **Ipamorelin alone in fish** (Fish · 2024): A cichlid-fish study administered ipamorelin and measured reproductive-axis hormones and tissue findings. Fish data do not establish a human endocrine outcome.[3] - **Unapproved-peptide safety review** (Review · 2026): A sports-medicine review assessed the limited human safety literature for unapproved peptides including ipamorelin. It did not test the CJC-1295 and ipamorelin combination.[4] - **Gerontology evidence gap** (Review · 2026): A gerontology review discussed the marketed combination and looked for validation and long-term safety data. It did not identify a human trial of the fixed mixture.[5] - **Unregulated product identity** (Analytical · 2018): High-resolution mass spectrometry identified a modified ipamorelin analogue in seized products. It did not analyze a Promise preparation or test a clinical outcome.[6] ## What the research can’t tell you - **No combination trial**: The cited research does not establish human efficacy, safety or pharmacokinetics for the mixture. General pathway synergy is not clinical proof.[5] - **CJC-1295 is not one fixed form**: With-DAC and no-DAC forms have different structures and expected persistence. A source about one cannot silently support the other. - **Human safety data are scarce**: A sports-medicine review says rigorous human safety data for unapproved peptides are scarce and notes the potential for serious harm. It did not define long-term risk for this combination.[4] - **Growth signaling raises a theoretical concern**: IGF-1 participates in cell growth and survival, creating a mechanism-based cancer question. That is not evidence that the combination causes cancer in people. - **Product identity can vary**: Analytical work on seized growth-hormone secretagogues found modified peptides. It cannot describe a specific prescription, but it shows why exact identity matters.[6] - **Prohibited in sport**: WADA names CJC-1295 among GHRH analogues and ipamorelin among growth-hormone secretagogues prohibited at all times.[7] ## FDA status Neither CJC-1295 nor ipamorelin is FDA-approved FDA’s page, content current as of April 22, 2026, lists CJC-1295 in the withdrawn-nomination table. FDA identifies immunogenicity and peptide-characterization concerns and reports increased heart rate and systemic vasodilatory reactions in its CJC-1295 entry.[8] Ipamorelin acetate is different: it appears in the withdrawn table and also remains in FDA’s safety-concern category under the 503B outsourcing-facility interim policy. FDA describes serious adverse events, including deaths, in an intravenous study; that report does not establish causation or quantify risk for another route.[8] Neither peptide appears on FDA’s finalized list of additional bulk substances for patient-specific compounding.[9] Promise Peptides is currently taking waitlist sign-ups. Joining is not a medical request and no prescription comes from it. ## A prescription route Promise is currently accepting waitlist signups. Joining is not a treatment request and does not result in a prescription. If treatment visits open, any treatment request would require clinical review; prescribing and pharmacy fulfillment would remain separate decisions. 1. **Start on Promise’s CJC-1295 + Ipamorelin page**: It shows what the treatment involves and its current availability. 2. **Answer the CJC-1295 + Ipamorelin questionnaire**: A licensed provider reviews health history, medicines and goals, and can decline. Not everyone qualifies. 3. **Pharmacy review is a separate step**: A prescription does not guarantee preparation or dispensing. A pharmacy must separately determine whether it can fulfill the prescription under the applicable requirements. A prescription does not make either peptide FDA-approved or supply the missing combination trial; it reflects a clinician’s review of an individual case. CJC-1295 + Ipamorelin at Promise Read the treatment information and view the current waitlist. [Join the Promise waitlist](https://mypromise.com/products/cjc-1295-ipamorelin?utm_source=peak&utm_medium=affiliate&utm_campaign=library&utm_content=cjc-1295-ipamorelin) Peak may earn money when readers become Promise patients. Joining does not guarantee future treatment availability. Availability would depend on the treatment, state, clinical review and separate pharmacy review. ## Questions ### Is CJC-1295 the same as ipamorelin? No. CJC-1295 copies a GHRH signal, while ipamorelin activates the ghrelin receptor. They are separate peptides with different structures and FDA histories. ### Has the combination been tested in people? No peer-reviewed human pharmacology trial of the premixed combination is identified in the cited research. Reviews describe a rationale and a major evidence gap.[5] ### Is ipamorelin FDA-approved? No. It remains an unapproved substance, with a separate and more restrictive FDA table entry from CJC-1295.[8] ## Sources 1. Cappola AR, et al. Hormones and aging: an Endocrine Society scientific statement. *J Clin Endocrinol Metab*. 2023;108:1835-1874. [PubMed 37326526](https://pubmed.ncbi.nlm.nih.gov/37326526/) 2. Devesa J. The complex world of regulation of pituitary growth hormone secretion: the role of ghrelin, klotho, and nesfatins in it. *Front Endocrinol*. 2021;12:636403. [PubMed 33776931](https://pubmed.ncbi.nlm.nih.gov/33776931/) 3. Gouda M, et al. The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish. *Anim Reprod Sci*. 2024;268:107550. [PubMed 38996787](https://pubmed.ncbi.nlm.nih.gov/38996787/) 4. Mendias CL, et al. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. *Sports Med*. 2026. [PubMed 41966639](https://pubmed.ncbi.nlm.nih.gov/41966639/) 5. Mavrych V, et al. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. *Front Aging*. 2026. [PubMed 42021992](https://pubmed.ncbi.nlm.nih.gov/42021992/) 6. Krug O, et al. Analysis of new growth promoting black market products. *Growth Horm IGF Res*. 2018;41:1-6. [PubMed 29864719](https://pubmed.ncbi.nlm.nih.gov/29864719/) 7. World Anti-Doping Agency. [The 2026 Prohibited List](https://www.wada-ama.org/en/prohibited-list) (S2.2.4). 8. U.S. Food and Drug Administration. [Certain bulk drug substances for use in compounding that may present significant safety risks](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks). Content current as of April 22, 2026. 9. U.S. Food and Drug Administration. [Bulk drug substances used in compounding under section 503A of the FD&C Act](https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act). ## Also in the library - [Sermorelin](https://peakpeptides.com/peptides/sermorelin/) (Growth hormone) - [MOTS-c](https://peakpeptides.com/peptides/mots-c/) (Mitochondrial peptide) - [NAD+](https://peakpeptides.com/peptides/nad-plus/) (Coenzyme) - [TB-500](https://peakpeptides.com/peptides/tb-500/) (Synthetic peptide) --- Peak maps the terrain; it does not examine anyone, so nothing here is medical advice, and the decision about any treatment belongs to a licensed provider who has reviewed your health. Peak may earn money when readers become Promise patients. Peak is not affiliated with any company called Peak Peptides or Peak Performance Peptides.